The article reports on the completion of the Phase III clinical trials for the CYD-TDV dengue virus vaccine developed by pharmaceutical company Sanofi-Aventis SA. The clinical trials highlight the effectiveness of the vaccine in preventing and treating mosquito-borne diseases. Also discussed are the clinical trials for other tetravalent dengue vaccines such as TAK-003 and TV-003.